Can the 875/125mg Tablet Be Used for Acute Otitis Media?
No, the 875 mg/125 mg amoxicillin/clavulanate tablet should not be used for acute otitis media (AOM) in pediatric patients, and the 600 mg/42.9 mg per 5 mL suspension formulation cannot be substituted with the 875/125 mg tablet.
Critical FDA Labeling Restrictions
The FDA drug label explicitly states that the 600 mg/42.9 mg per 5 mL suspension is specifically indicated for pediatric patients with recurrent or persistent AOM and contains a different ratio of clavulanic acid that is not interchangeable with other formulations 1. The label further specifies that adults who have difficulty swallowing should NOT be given the 600 mg/42.9 mg per 5 mL suspension in place of the 500 mg/125 mg or 875 mg/125 mg tablet 1. This indicates these formulations serve different populations and are not interchangeable.
Why the 875/125mg Tablet Is Inappropriate
The 875/125 mg tablet formulation provides:
- 875 mg amoxicillin with 125 mg clavulanate in a fixed ratio
- This is designed for adult dosing (typically twice daily)
- The clavulanate ratio differs significantly from pediatric high-dose formulations
For pediatric AOM requiring high-dose therapy, guidelines recommend 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in a 14:1 ratio 2, 1. The 875/125 mg tablet has approximately a 7:1 ratio, which provides excessive clavulanate relative to amoxicillin for the intended pediatric dosing strategy.
Correct Treatment Algorithm After Initial Failure
When a patient fails initial amoxicillin 500/125 mg treatment for AOM:
Switch to high-dose amoxicillin-clavulanate: Use the 600 mg/42.9 mg per 5 mL suspension at 90 mg/kg/day of amoxicillin divided every 12 hours 2
If high-dose amoxicillin-clavulanate fails: Consider intramuscular ceftriaxone 50 mg/kg for 3 days 2
For repeated failures: Tympanocentesis with culture and susceptibility testing should be performed 2
Evidence Supporting High-Dose Formulation
The 600 mg/42.9 mg per 5 mL formulation demonstrated 98.4% bacteriologic eradication of S. pneumoniae (including 85.7% of strains with penicillin MIC = 4 mcg/mL) in clinical trials 1, 3. This formulation was specifically developed to address penicillin-resistant S. pneumoniae while minimizing clavulanate-related diarrhea by maintaining the same total daily clavulanate dose as standard formulations 4.
Common Pitfall to Avoid
Do not attempt to achieve high-dose amoxicillin by using multiple 875/125 mg tablets or combining formulations. This would result in excessive clavulanate exposure, significantly increasing the risk of diarrhea (already occurring in 40-43% of patients on appropriate formulations) 1. The 14:1 ratio in the 600 mg/42.9 mg per 5 mL suspension was specifically engineered to provide adequate amoxicillin while limiting clavulanate-associated adverse effects 1, 4.
Age and Weight Considerations
The 600 mg/42.9 mg per 5 mL suspension is indicated for pediatric patients 3 months and older weighing up to 40 kg 1. For patients weighing ≥40 kg or adults, experience with this formulation is not available, and alternative formulations should be used 1.